Sökning: WFRF:(Jansson Per Anders)
> (2015-2019) >
Probiotic treatment...
Probiotic treatment using a mix of three Lactobacillus strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial
-
- Jansson, Per-Anders, 1961 (författare)
- Gothenburg University,Göteborgs universitet,Wallenberglaboratoriet,Wallenberg Laboratory
-
Curiac, D. (författare)
-
Ahren, I. L. (författare)
-
visa fler...
-
Hansson, F. (författare)
-
Niskanen, T. M. (författare)
-
- Sjögren, Klara, 1970 (författare)
- Gothenburg University,Göteborgs universitet,Centre for Bone and Arthritis Research
-
- Ohlsson, Claes, 1965 (författare)
- Gothenburg University,Göteborgs universitet,Centre for Bone and Arthritis Research
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2019
- 2019
- Engelska.
-
Ingår i: Lancet Rheumatology. - : Elsevier BV. - 2665-9913. ; 1:3
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Postmenopausal bone loss in the spine is associated with an increased risk of vertebral fractures. Certain probiotic treatment protects rodents from ovariectomy-induced bone loss. The aim of the present study was to determine if treatment with a combination of three bacterial strains protects against the rapid spine bone loss occurring in healthy early postmenopausal women. Methods This randomised, double-blind, placebo-controlled, multicentre trial was done at four study centres in Sweden. Early postmenopausal women were randomly assigned in a 1:1 ratio to receive probiotic treatment consisting of three Lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, and Lactobacillus plantarum DSM 15313; 1 x 10(10 )colony-forming units per capsule) or placebo once daily for 12 months. The primary outcome was the percentage change from baseline in lumbar spine bone mineral density (LS-BMD) at 12 months. The primary analysis was done in all participants with BMD measurements available both at baseline and at 12 months. Analyses of adverse events and safety included all participants who had taken at least one capsule of placebo or Lactobacillus. This trial is registered with ClinicalTrials.gov, NCT02722980, and is completed. Findings Between April 18 and Nov 11,2016,249 participants were randomly assigned to receive probiotic product or placebo, and 234 (94%) completed the analyses required for the primary outcome. Lactobacillus treatment reduced the LS-BMD loss compared with placebo (mean difference 0.71%, 95% CI 0.06 to 1.35). The LS-BMD loss was significant in the placebo group (-0.72%, -1.22 to -0.22), whereas no bone loss was observed in the Lactobacillus-treated group (-0.01%, -0.50 to 0.48). The adverse events were similar between the two groups. Interpretation Probiotic treatment using a mix of three Lactobacillus strains protects against lumbar spine bone loss in healthy postmenopausal women. Copyright (C) 2019 Elsevier Ltd. All rights reserved.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Nyckelord
- mineral density
- gut microbiota
- deficiency
- fragility
- mass
- Rheumatology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas